explore -WSS

explore

author：explore 2025-09-27 13:05:18 - browse：26718

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Laying a path for careers in science

entertainment

leisure time

WSS

Judge denies Trump's request for new trial in E. Jean Carroll case

Elisabeth Bik tackles the widespread issue of research misconduct

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

'Vaccine

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Laying a path for careers in science

knowledge

explore

explore

Anesthesiologist group: stop taking Ozempic before surgery

STAT Madness 2024: Meet the contenders

Psychedelics group wrestles with new pharma identity

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Jerome Adams on the need for new antivirals for Covid

Medicare Advantage isn’t working — for anyone

The cancer drug shortage isn’t new — and neither are the solutions

Mystery swirls around US soldier who entered North Korea days ago, officials say

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

knowledge

Neuroscience renaissance leads to new crop of psychiatric drugs

Doctor of U.S. President Joe Biden says he is fit for duty

Delta passengers in Vegas fall sick while waiting on flight in triple

Change Healthcare cyberattack shows risk of industry consolidation

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

leisure time

entertainment

leisure time

focus